Ariad Pharmaceuticals Inc fka ARIA

[adreamer]

Analysts at Oppenheimer initiated coverage on shares of Ariad Pharmaceutical (NASDAQ: ARIA) in a research report issued to clients and investors on Wednesday. The firm set an “outperform” rating on the stock.

ARIA has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “buy (n/a)” rating on shares of Ariad Pharmaceutical in a research note to investors on Wednesday, June 6th. Separately, analysts at Barclays Capital reiterated an “overweight” rating on shares of Ariad Pharmaceutical in a research note to investors on Tuesday, June 5th. Finally, analysts at Summer Street raised their price target on shares of Ariad Pharmaceutical to $21.00 in a research note to investors on Monday, May 14th.